Thermo Fisher unveils the Gibco CTS Compleo system to automate cell therapy manufacturing, targeting efficiency gains and consistency as demand in the fast-growing market rises.
The April 2026 Top 25 High Growth Dividend Stocks list targets quality companies trading below intrinsic value, averaging a 1.52% yield and 17.7% five-year dividend growth. Screened stocks appear ~34% undervalued by dividend yield theory, with an estimated +21% annualized long-term return potential. MSCI, WING, ZTS, INTU, and MSFT stand out for attractive valuations, robust dividend growth, and strong projected EPS growth.
Thermo Fisher may gain as it unveils its Gibco CHOvantage GS CLD Kit to speed biologics development, cut costs and boost cell culture growth.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the global launch of the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing. Because cell therapies often begin with patient-derived cells, manufacturing workflows must accommodate variability in cell count, concentration and viability. As more therapies move toward c.
Capital Advisors Inc. OK bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,141 shares of the medical research company's stock, valued at approximately $661,000. Other
Compagnie Lombard Odier SCmA raised its stake in Thermo Fisher Scientific Inc. (NYSE: TMO) by 2.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 299,655 shares of the medical research company's stock after acquiring an additional 5,895 shares during the period.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability. Global pipelines for protein therapeutics, including complex biologics and biosimilars used to treat conditions ranging from cancer to autoimmune and rare diseases, continue to expand. This.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2026 before the market opens on Thursday, April 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the “Investors” section of our website, www.thermofish.
DarioHealth (NASDAQ: DRIO - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 33.4% of DarioHealth shares
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before. The Thermo Scientific™ Glacios™ 3 Cryo-TEM offers researchers the next major advancement in 200 kV imaging and structural analysis. Cryogenic electron microscopy (cryo-EM), an.
